NO20034992D0 - Nye 4-aninlinokinolin-3-karboksamider - Google Patents
Nye 4-aninlinokinolin-3-karboksamiderInfo
- Publication number
- NO20034992D0 NO20034992D0 NO20034992A NO20034992A NO20034992D0 NO 20034992 D0 NO20034992 D0 NO 20034992D0 NO 20034992 A NO20034992 A NO 20034992A NO 20034992 A NO20034992 A NO 20034992A NO 20034992 D0 NO20034992 D0 NO 20034992D0
- Authority
- NO
- Norway
- Prior art keywords
- aninlinoquinoline
- carboxamides
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101675A SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Novel composition |
PCT/SE2002/000875 WO2002092571A1 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20034992D0 true NO20034992D0 (no) | 2003-11-10 |
Family
ID=20284085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034992A NO20034992D0 (no) | 2001-05-11 | 2003-11-10 | Nye 4-aninlinokinolin-3-karboksamider |
Country Status (25)
Country | Link |
---|---|
US (2) | US7037925B2 (pt) |
EP (1) | EP1387830A1 (pt) |
JP (1) | JP2004533452A (pt) |
KR (1) | KR20040007547A (pt) |
CN (1) | CN1286815C (pt) |
AR (1) | AR037489A1 (pt) |
BG (1) | BG108325A (pt) |
BR (1) | BR0209431A (pt) |
CA (1) | CA2446717A1 (pt) |
CZ (1) | CZ20033034A3 (pt) |
EE (1) | EE200300544A (pt) |
HU (1) | HUP0401339A2 (pt) |
IL (1) | IL158517A0 (pt) |
IS (1) | IS7016A (pt) |
MX (1) | MXPA03010207A (pt) |
MY (1) | MY134136A (pt) |
NO (1) | NO20034992D0 (pt) |
NZ (1) | NZ529302A (pt) |
PL (1) | PL366766A1 (pt) |
RU (1) | RU2281940C2 (pt) |
SE (1) | SE0101675D0 (pt) |
SK (1) | SK13712003A3 (pt) |
UA (1) | UA76142C2 (pt) |
WO (1) | WO2002092571A1 (pt) |
ZA (1) | ZA200308350B (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
CN100471842C (zh) | 2003-07-24 | 2009-03-25 | 安斯泰来制药有限公司 | 喹诺酮衍生物或其盐 |
DK2210607T3 (da) | 2003-09-26 | 2011-12-12 | Exelixis Inc | N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft |
GB0322722D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
SE0400284D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
CA2563569A1 (en) * | 2004-05-03 | 2005-11-10 | Novartis Ag | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
AU2005293336B2 (en) | 2004-10-12 | 2009-05-28 | Astrazeneca Ab | Quinazoline derivatives |
KR100867071B1 (ko) * | 2004-10-19 | 2008-11-04 | 에프. 호프만-라 로슈 아게 | 퀴놀린 유도체 |
DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
JP2009528336A (ja) * | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キノリン誘導体 |
UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
CA2645376C (en) | 2006-03-13 | 2017-06-20 | Activx Biosciences, Inc. | Aminoquinolones as gsk-3 inhibitors |
TW200808732A (en) * | 2006-04-14 | 2008-02-16 | Astrazeneca Ab | Chemical compounds |
WO2007139496A1 (en) * | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
EP2203458B1 (en) * | 2007-09-11 | 2011-11-02 | Kyorin Pharmaceutical Co., Ltd. | Cyanoaminoquinolones as gsk-3 inhibitors |
MX2010002662A (es) | 2007-09-12 | 2010-04-09 | Activx Biosciences Inc | Aminoquinolonas espirociclicas como inhibidores de gsk-3. |
PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP2310375A1 (en) * | 2008-05-07 | 2011-04-20 | AstraZeneca AB | Chemical compounds |
EP2361902A4 (en) * | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
WO2010083414A1 (en) | 2009-01-16 | 2010-07-22 | Exelixis, Inc. | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
AU2010221990B2 (en) | 2009-03-11 | 2015-06-04 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones as GSK-3 inhibitors |
US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US9120749B2 (en) | 2010-07-30 | 2015-09-01 | Oncotherapy Science, Inc. | Quinoline derivatives and MELK inhibitors containing the same |
UY33549A (es) * | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
KR101940340B1 (ko) | 2011-03-04 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 아미노-퀴놀린 |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
IN2014CN04065A (pt) | 2011-11-23 | 2015-09-04 | Portola Pharm Inc | |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
EP2958895B1 (en) | 2013-02-20 | 2020-08-19 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
KR20150118152A (ko) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 퀴나졸린 |
CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2016125187A1 (en) * | 2015-02-03 | 2016-08-11 | Council Of Scientific & Industrial Research | Novel quinoline derivatives and preparation thereof |
EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
US10723701B2 (en) | 2016-10-18 | 2020-07-28 | Beijing Konruns Pharmaceutical Co., Ltd. | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037925A (en) * | 1958-04-09 | 1962-06-05 | Smith Corp A O | Cathodically protected structure and method of making same |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
WO2000010981A1 (en) | 1998-08-21 | 2000-03-02 | Parker Hughes Institute | Quinazoline derivatives |
-
2001
- 2001-05-11 SE SE0101675A patent/SE0101675D0/xx unknown
-
2002
- 2002-05-03 AR ARP020101633A patent/AR037489A1/es not_active Application Discontinuation
- 2002-05-06 NZ NZ529302A patent/NZ529302A/en unknown
- 2002-05-06 BR BR0209431-2A patent/BR0209431A/pt not_active IP Right Cessation
- 2002-05-06 US US10/477,254 patent/US7037925B2/en not_active Expired - Fee Related
- 2002-05-06 CA CA002446717A patent/CA2446717A1/en not_active Abandoned
- 2002-05-06 MX MXPA03010207A patent/MXPA03010207A/es unknown
- 2002-05-06 JP JP2002589457A patent/JP2004533452A/ja active Pending
- 2002-05-06 RU RU2003131679/04A patent/RU2281940C2/ru not_active IP Right Cessation
- 2002-05-06 CN CNB02809722XA patent/CN1286815C/zh not_active Expired - Fee Related
- 2002-05-06 CZ CZ20033034A patent/CZ20033034A3/cs unknown
- 2002-05-06 PL PL02366766A patent/PL366766A1/xx unknown
- 2002-05-06 KR KR10-2003-7014579A patent/KR20040007547A/ko not_active Application Discontinuation
- 2002-05-06 SK SK13712003A patent/SK13712003A3/sk unknown
- 2002-05-06 EE EEP200300544A patent/EE200300544A/xx unknown
- 2002-05-06 HU HU0401339A patent/HUP0401339A2/hu unknown
- 2002-05-06 WO PCT/SE2002/000875 patent/WO2002092571A1/en active IP Right Grant
- 2002-05-06 IL IL15851702A patent/IL158517A0/xx unknown
- 2002-05-06 EP EP02733657A patent/EP1387830A1/en not_active Withdrawn
- 2002-05-09 MY MYPI20021680A patent/MY134136A/en unknown
- 2002-06-05 UA UA2003109525A patent/UA76142C2/uk unknown
-
2003
- 2003-10-27 ZA ZA200308350A patent/ZA200308350B/en unknown
- 2003-11-05 IS IS7016A patent/IS7016A/is unknown
- 2003-11-07 BG BG108325A patent/BG108325A/bg unknown
- 2003-11-10 NO NO20034992A patent/NO20034992D0/no not_active Application Discontinuation
-
2006
- 2006-03-06 US US11/368,914 patent/US20060173034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IS7016A (is) | 2003-11-05 |
RU2281940C2 (ru) | 2006-08-20 |
IL158517A0 (en) | 2004-05-12 |
ZA200308350B (en) | 2005-01-27 |
HU0401339D0 (en) | 2004-08-30 |
NZ529302A (en) | 2004-08-27 |
US7037925B2 (en) | 2006-05-02 |
HUP0401339A2 (hu) | 2004-12-28 |
US20060173034A1 (en) | 2006-08-03 |
CZ20033034A3 (en) | 2004-06-16 |
MXPA03010207A (es) | 2004-03-10 |
BR0209431A (pt) | 2004-08-03 |
EE200300544A (et) | 2004-02-16 |
PL366766A1 (en) | 2005-02-07 |
CN1507434A (zh) | 2004-06-23 |
WO2002092571A1 (en) | 2002-11-21 |
BG108325A (bg) | 2004-11-30 |
CA2446717A1 (en) | 2002-11-21 |
CN1286815C (zh) | 2006-11-29 |
US20040248923A1 (en) | 2004-12-09 |
JP2004533452A (ja) | 2004-11-04 |
RU2003131679A (ru) | 2005-05-10 |
UA76142C2 (en) | 2006-07-17 |
MY134136A (en) | 2007-11-30 |
SE0101675D0 (sv) | 2001-05-11 |
EP1387830A1 (en) | 2004-02-11 |
KR20040007547A (ko) | 2004-01-24 |
SK13712003A3 (en) | 2004-10-05 |
AR037489A1 (es) | 2004-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20035428D0 (no) | Nye anti-ineffektiver | |
NO20034992D0 (no) | Nye 4-aninlinokinolin-3-karboksamider | |
NO20040014L (no) | Nye forbindelser | |
NO20041003L (no) | Nye forbindelser | |
NO20034665L (no) | Nye forbindelser | |
NO20034308D0 (no) | Nye tyrokinase-inhibitorer | |
NO20026064L (no) | Nye forbindelser | |
NO20023932L (no) | Nye forbindelser | |
ATE402148T1 (de) | Substituierte pyridinylamine | |
NO20034970D0 (no) | Nye arylheteroalkylaminderivater | |
NO20044588L (no) | Nye forbindelser | |
NO20044432L (no) | Nye forbindelser | |
DE50206892D1 (de) | Substituierte imidazotriazinone | |
NO20034773D0 (no) | Nye ftalazinoner | |
NO20025151D0 (no) | Nye forbindelser | |
NO20031141D0 (no) | Nye forbindelser | |
NO20034695D0 (no) | Nye sammensetninger | |
NO20040066L (no) | Nye antikonvulsivaderivater | |
NO20014597D0 (no) | Fremgangsmåte | |
NO20041185L (no) | Nye sykloheksylsulfoner | |
NO20026162D0 (no) | Nye forbindelser | |
DK1373228T3 (da) | Substituerede fluoralkoxyphenylsulfonylurinstoffer | |
IS2523B (is) | Turn vindorkuvers | |
NO20030274L (no) | Nye aryleten-sulfonamider | |
NO20026081D0 (no) | Nye forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |